NRIX•benzinga•
Sanofi Has Exercised Its Option To Exclusively License Nurix Therapeutics' STAT6 Program, Including The Drug Development Candidate NX-3911, Nurix To Receive A $15M License Extension Fee From Sanofi Under Its 2019 Collaboration Agreement
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga